ArticleBreast cancer research : BCR2026
Prognostic significance of clinicopathological parameters, margin width and locoregional recurrences on outcome of primary and radiation associated breast angiosarcoma- results from a large UK sarcoma regional service.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sinonasal hemangiosarcoma following juvenile occupational exposure to formaldehyde when breeding farm animals.Annals of occupational and environmental medicine · 2026Article
- Giant Breast Angiosarcoma in a 20-Year-Old Young Adult Female: A Case Report and Review of Literature.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast angiosarcomas (AS) are rare and aggressive malignancies, categorised as primary angiosarcoma (PAS) and radiation-associated angiosarcoma (RAAS). Due to its rarity, large series of PAS and RAAS are limited. We aimed to analyse the outcome of a large cohort of angiosarcomas with emphasis on the prognostic factors, latency, margin width and significance of locoregional recurrences.
methodsA retrospective study was conducted on angiosarcomas managed at a large UK Regional Sarcoma Centre between 2013 and 2024. Clinical, pathological, disease-free survival (DFS) and overall survival (OS) data were collected. The interval between radiotherapy delivery and the development of angiosarcoma was calculated. Cox regression models and binary logistic regression were utilised for optimal threshold values for resection margins and patient outcomes.
resultsPAS presented at a younger age (median 31 vs 71 years for RAAS). A significant shortening of latency between radiotherapy and onset of RAAS was found (r = − 0.719, p < 0.001). DFS and OS were 59.6%, and 54.2% respectively. Smaller microscopic resection margins were significantly associated with recurrence (p = 0.001). Recurrence was a strong predictor of mortality, HR = 2.856, p = 0.005. Mean survival with and without angiosarcoma recurrences was 32.9 and 80.5 months respectively (p = 0.005). Resection margins ≥ 10 mm were significantly associated with lower rates of recurrences (p = 0.044, OR = 0.323). However, resection margin distance did not directly impact survival (HR = 1.002, p = 0. 798). Cox regression analysis showed angiosarcoma size was not a predictor of survival (p = 0.278, HR = 1.002). Neither patient age nor the angiosarcoma histological grade correlated with recurrences or patient survival. C-Myc immunohistochemistry was positive in four of nine (44.44%) PASs and in 95.52% of RAAS. Its expression did not correlate with patient survival.
conclusionOver the last decade, the number of diagnosed RAAS cases has increased with a shortening in the interval between radiotherapy and onset of RAAS. Margin status and recurrences, but not angiosarcoma grade or size, impact survival. Achieving a clear surgical margin is therefore critical for improved patients’ outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.